RPS17D Antibody

What is RPS17 and what is its biological significance?

RPS17 (ribosomal protein S17) is a critical component of the small (40S) ribosomal subunit, functioning within the larger ribonucleoprotein complex responsible for cellular protein synthesis. This 135 amino acid protein has a molecular weight of approximately 16 kDa and belongs to the S17e family of ribosomal proteins . RPS17 is localized primarily to the cytoplasm and is expressed ubiquitously across various tissues. The protein plays an essential role in ribosome assembly and mRNA translation. Notably, mutations in the RPS17 gene are associated with Diamond-Blackfan anemia (DBA), a rare congenital disorder characterized by defective differentiation of pro-erythroblasts . Like many other ribosomal proteins, the RPS17 gene has generated multiple processed pseudogenes scattered throughout the genome, which presents unique challenges for research specificity.

What are the different types of RPS17 antibodies available for research?

Researchers can choose between polyclonal and monoclonal RPS17 antibodies depending on their specific experimental needs. Polyclonal antibodies, such as the 16267-1-AP, are derived from rabbit hosts and recognize multiple epitopes on the RPS17 protein . These antibodies are purified through antigen affinity chromatography methods . In contrast, monoclonal antibodies, like the mouse-derived clone 1B11, recognize a single epitope and offer higher specificity for certain applications . There are also recombinant antibodies, such as the 83848-4-RR, which combine specificity advantages with consistent production characteristics . When selecting between these antibody types, researchers should consider factors including the specific application, required sensitivity, and potential cross-reactivity concerns.

What are the validated applications for RPS17 antibodies?

RPS17 antibodies have been validated for multiple research applications. Western Blot (WB) analysis is commonly performed with dilutions ranging from 1:500-1:2000 for polyclonal antibodies and 1:5000-1:50000 for recombinant antibodies . Immunohistochemistry (IHC) applications typically use dilutions of 1:50-1:500 . For immunofluorescence (IF) and immunocytochemistry (ICC), recommended dilutions range from 1:125-1:800 depending on the specific antibody . Flow cytometry applications have also been validated, with recommendations of 0.25 μg per 10^6 cells in a 100 μl suspension . Enzyme-linked immunosorbent assay (ELISA) represents another validated application, though specific dilution recommendations vary based on the particular assay design.

What are the optimal conditions for using RPS17 antibodies in Western Blot experiments?

For optimal Western Blot results with RPS17 antibodies, researchers should consider the following methodological approach: Begin with protein extraction from appropriate cell lines where positive detection has been confirmed, such as HEK-293, HeLa, Jurkat, A549, or NIH/3T3 cells . Load 20-30 μg of total protein per lane on a 12-15% SDS-PAGE gel to achieve optimal separation of the relatively small (16 kDa) RPS17 protein. After transferring proteins to a PVDF or nitrocellulose membrane, block with 5% non-fat milk or BSA in TBST for 1-2 hours at room temperature. Apply primary RPS17 antibody at the manufacturer-recommended dilution (ranging from 1:500-1:50000 depending on the specific antibody) and incubate overnight at 4°C. Following thorough washing, apply appropriate HRP-conjugated secondary antibody and develop using enhanced chemiluminescence. The expected band should appear at approximately 16 kDa, matching the observed molecular weight reported in product specifications .

How should I optimize immunohistochemistry protocols when using RPS17 antibodies?

When optimizing immunohistochemistry protocols with RPS17 antibodies, consider these critical parameters: For tissue preparation, both frozen and paraffin-embedded samples can be used, though positive detection has been specifically documented in mouse cerebellum tissue . For paraffin sections, antigen retrieval is crucial—use TE buffer at pH 9.0 as suggested, or alternatively, citrate buffer at pH 6.0 . Block endogenous peroxidase activity with 3% hydrogen peroxide followed by protein blocking with 5-10% normal serum. Apply the primary RPS17 antibody at dilutions between 1:50-1:500 , with initial testing at 1:100, and incubate overnight at 4°C. Use an appropriate detection system (e.g., HRP-polymer) and develop with DAB substrate. Counterstain with hematoxylin for nuclear visualization. For each experiment, include positive controls (cerebellum tissue) and negative controls (primary antibody omission). Begin with the manufacturer's recommended protocol and adjust incubation times and antibody dilutions based on your specific tissue and detection sensitivity requirements.

What controls should be included when using RPS17 antibodies in immunofluorescence studies?

Robust immunofluorescence experiments with RPS17 antibodies require several critical controls. First, include a positive control using cell lines where RPS17 antibody reactivity has been confirmed, such as U2OS cells, which have demonstrated positive IF/ICC detection . Second, implement negative controls by omitting the primary antibody while maintaining all other steps, which helps identify potential non-specific binding from secondary antibodies. Third, consider including a peptide competition control where the RPS17 antibody is pre-incubated with excess immunizing peptide before application, which should substantially reduce specific staining. Fourth, as RPS17 is ubiquitously expressed, a knockdown or knockout control using siRNA or CRISPR-Cas9 targeting RPS17 can validate antibody specificity. Fifth, consider dual staining with antibodies against other ribosomal proteins (e.g., RPS6) to confirm expected co-localization patterns in the cytoplasm. Finally, include a nuclear counterstain (DAPI) to visualize cellular architecture and verify the expected cytoplasmic localization of RPS17 staining.

How can RPS17 antibodies be used to study Diamond-Blackfan anemia (DBA)?

RPS17 antibodies offer valuable tools for investigating Diamond-Blackfan anemia, a rare congenital disorder linked to RPS17 gene mutations . For comprehensive DBA research, implement these methodological approaches: First, use Western blotting to quantitatively compare RPS17 protein levels between patient-derived samples and healthy controls, which can reveal potential haploinsufficiency patterns. Second, employ immunofluorescence to examine RPS17 subcellular localization in erythroid progenitor cells, potentially revealing abnormal distribution patterns in DBA patients. Third, combine RPS17 antibodies with cell fractionation techniques to assess incorporation of the protein into pre-ribosomal particles, which may be impaired in DBA. Fourth, use co-immunoprecipitation with RPS17 antibodies followed by mass spectrometry to identify altered protein interaction networks in DBA patient cells. Fifth, apply RPS17 antibodies in ribosome profiling experiments to detect changes in translation efficiency of specific mRNAs in DBA. Finally, develop immunohistochemistry panels including RPS17 and erythroid lineage markers to examine bone marrow samples from DBA patients, potentially revealing stages of erythropoiesis most affected by RPS17 deficiency.

What techniques can be combined with RPS17 antibodies to study ribosome biogenesis?

Advanced ribosome biogenesis research can leverage RPS17 antibodies in several sophisticated methodological approaches. First, researchers can combine sucrose gradient fractionation with Western blotting using RPS17 antibodies to track the incorporation of this protein into pre-ribosomal particles and mature ribosomes. Second, chromatin immunoprecipitation (ChIP) using antibodies against transcription factors involved in ribosomal RNA expression, followed by immunoblotting for RPS17, can reveal regulatory mechanisms of coordinated ribosome assembly. Third, proximity ligation assays (PLA) using RPS17 antibodies paired with antibodies against other ribosomal proteins or assembly factors can visualize and quantify specific interaction events during ribosome biogenesis. Fourth, pulse-chase experiments with metabolic labeling followed by immunoprecipitation with RPS17 antibodies can determine protein turnover rates in different cellular compartments. Fifth, the combination of SILAC (Stable Isotope Labeling with Amino acids in Cell culture) with immunoprecipitation using RPS17 antibodies enables quantitative proteomics to identify novel interaction partners during ribosome assembly. Finally, implementing super-resolution microscopy with fluorescently tagged RPS17 antibodies can visualize the dynamics of ribosome assembly at unprecedented resolution.

What are the challenges in distinguishing between RPS17 and its pseudogenes in research?

Distinguishing between functional RPS17 and its pseudogenes presents significant challenges that require carefully designed experimental approaches. Like many ribosomal proteins, RPS17 exists as multiple processed pseudogenes scattered throughout the genome , which can complicate both genomic and transcriptomic analyses. At the DNA/RNA level, researchers should design PCR primers that span intron-exon boundaries of the functional RPS17 gene, as pseudogenes typically lack introns. For RT-PCR and qPCR, careful primer design targeting unique regions of the functional transcript is essential. At the protein level, RPS17 antibodies may not inherently distinguish between products of the functional gene versus transcribed and translated pseudogenes with high sequence similarity. Therefore, researchers should conduct specificity validation through multiple approaches: First, test antibody reactivity in cells where RPS17 has been knocked down by targeted siRNAs. Second, perform peptide competition assays to confirm epitope specificity. Third, compare staining patterns with multiple RPS17 antibodies recognizing different epitopes. Fourth, use mass spectrometry following immunoprecipitation to confirm the exact protein sequence being detected. Finally, researchers should be aware that in certain cellular contexts or disease states, some pseudogenes might be transcribed and even translated, potentially complicating the interpretation of RPS17 antibody-derived data.

What are common causes of non-specific binding when using RPS17 antibodies?

Non-specific binding when using RPS17 antibodies can arise from several experimental factors that require systematic troubleshooting. First, insufficient blocking can lead to high background—optimize by testing different blocking agents (BSA, normal serum, commercial blockers) and extending blocking time to 2 hours at room temperature. Second, excessively high antibody concentrations may increase non-specific interactions—perform antibody titration experiments starting from the manufacturer's recommended dilution and testing more dilute solutions (e.g., 1:1000, 1:2000, 1:5000 for Western blot) . Third, inadequate washing between incubation steps can leave residual unbound antibody—increase both the number of washes (5-6 times) and their duration (10 minutes each). Fourth, cross-reactivity with similar epitopes on other proteins may occur—validate by testing the antibody on lysates from RPS17 knockdown cells. Fifth, some cell or tissue types may express proteins that non-specifically bind antibodies through their Fc regions—try using F(ab')2 fragments instead of whole IgG antibodies. Sixth, for immunohistochemistry applications, endogenous peroxidase or phosphatase activity might contribute to background—ensure proper quenching steps are included. Finally, some fixation methods may alter epitope conformation or accessibility—compare results using different fixation protocols (4% PFA, methanol, acetone) to identify optimal conditions.

How can I validate the specificity of my RPS17 antibody?

Rigorous validation of RPS17 antibody specificity requires a multi-faceted approach combining complementary techniques. First, conduct Western blot analysis using cell lysates from multiple cell lines where RPS17 is expressed (HEK-293, HeLa, Jurkat, A549, NIH/3T3) to confirm detection of a single band at the expected molecular weight of 16 kDa. Second, perform peptide competition assays by pre-incubating the antibody with excess immunizing peptide before application, which should substantially reduce or eliminate specific signal. Third, implement genetic validation through siRNA knockdown or CRISPR-Cas9 knockout of RPS17, which should result in corresponding reduction or loss of antibody signal. Fourth, compare results from multiple antibodies targeting different RPS17 epitopes—consistent detection patterns across antibodies increase confidence in specificity. Fifth, perform immunoprecipitation followed by mass spectrometry to confirm that the pulled-down protein is indeed RPS17. Sixth, test the antibody on samples from different species to verify cross-reactivity claims (human, mouse) . Finally, for recombinant antibodies, utilize surface plasmon resonance (SPR) or enzyme-linked immunosorbent assays (ELISA) with purified RPS17 protein to quantitatively measure binding affinity and specificity.

What approaches can resolve discrepancies in RPS17 detection between different techniques?

When facing discrepancies in RPS17 detection across different techniques, researchers should implement a systematic resolution approach. First, consider epitope accessibility variations—the RPS17 epitope may be differentially exposed depending on the technique (denatured in Western blot versus native conformation in immunofluorescence). Test antibodies specifically validated for each application rather than assuming cross-application functionality . Second, evaluate fixation and sample preparation effects—compare paraformaldehyde, methanol, and acetone fixation for immunofluorescence, or test different lysis buffers for Western blot to optimize epitope preservation. Third, adjust antibody concentration systematically across techniques—while Western blot may require 1:500-1:2000 dilution, immunofluorescence might need 1:200-1:800 for optimal results . Fourth, implement technical controls specific to each method—for flow cytometry, include isotype controls; for immunoprecipitation, use non-specific IgG. Fifth, consider the detection sensitivity threshold of each technique—flow cytometry might detect lower expression levels than Western blot. Sixth, evaluate potential post-translational modifications that might affect epitope recognition in different contexts. Finally, develop a multi-technique validation approach where findings from one method (e.g., immunofluorescence) are confirmed by an orthogonal technique (e.g., proximity ligation assay) to establish consensus on RPS17 detection patterns.

What are the optimal storage conditions for maintaining RPS17 antibody activity?

Maintaining optimal RPS17 antibody activity requires strict adherence to recommended storage conditions. The manufacturer specifications indicate that RPS17 antibodies should be stored at -20°C for long-term preservation . The antibodies are typically supplied in PBS with 0.02% sodium azide and 50% glycerol at pH 7.3, a formulation designed to prevent freezing at -20°C and maintain antibody stability . Under these conditions, the antibodies remain stable for at least one year after shipment, according to manufacturer guarantees . For antibodies in liquid form, it's important to minimize exposure to light and avoid contamination by using sterile technique when handling. Some preparations may contain BSA (e.g., 0.1% in certain 20 μl size offerings) , which serves as a stabilizing protein. For working solutions, store at 4°C for short periods (1-2 weeks) but avoid extended storage at this temperature as it may compromise antibody performance. Always centrifuge the antibody vial briefly before opening to collect the liquid at the bottom of the vial, especially after shipment or any physical disturbance.

What buffer conditions are recommended for diluting RPS17 antibodies for various applications?

Optimal buffer conditions for diluting RPS17 antibodies vary based on the specific application. For Western blot applications, prepare antibody dilutions (1:500-1:2000 for polyclonal or 1:5000-1:50000 for recombinant antibodies ) in TBST (TBS with 0.1% Tween-20) containing 5% non-fat milk or 5% BSA. For immunohistochemistry applications using dilutions of 1:50-1:500 , prepare antibodies in IHC antibody diluent containing 1% BSA in PBS with 0.025-0.05% Tween-20. When performing immunofluorescence at recommended dilutions of 1:200-1:800 or 1:125-1:500 , use PBS containing 1% BSA and 0.3% Triton X-100 for permeabilized cells, or simply 1% BSA in PBS for surface staining. For flow cytometry applications, the recommended concentration is 0.25 μg per 10^6 cells in a 100 μl suspension , typically prepared in flow cytometry staining buffer containing 1-2% FBS in PBS with 0.1% sodium azide. Across all applications, freshly prepared dilutions yield optimal results. The manufacturer emphasizes that "this reagent should be titrated in each testing system to obtain optimal results" , indicating that buffer conditions and dilutions may need adjustment based on specific experimental conditions and sample types.